StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
AKTX stock opened at $1.64 on Friday. The firm has a 50 day moving average of $1.63 and a 200-day moving average of $2.47. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $5.50.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC raised its holdings in shares of Akari Therapeutics, Plc (NASDAQ:AKTX – Free Report) by 48.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities & Exchange Commission. 5.06% of the stock is currently owned by hedge funds and other institutional investors.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
See Also
- Five stocks we like better than Akari Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- Roblox: The Bottom Just Fell Out of the Metaverse
- How to Invest in Biotech Stocks
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.